Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna--a clinical and urodynamic study.
To find the efficacy and optimal dosage of oxybutynin HC1 in a group of enuretic children, who were non-responsive to imipramine. Thirty-six patients with enuresis who were non-responsive to imipramine were urodynamically assessed and subsequently treated with oxybutynin hydrochloride (HCl). Patients with inadequate bladder storage function (IBSF) were started on 10-mg daily oxybutynin HCl for one month. If the initial treatment was found to be inadequate, the dose was increased to 15 mg daily. The dose in patients who were non-responsive to 15-mg daily dose was increased to 20-mg daily dose. Patients who were normal urodynamically were treated with a dose of 15 mg daily for one month. Before the treatment, 17 patients had IBSF (47.2%). The majority of the patients (88.2%) with IBSF were responsive to the 15-mg daily oxybutynin HCl. The treatment in patients with normal bladder function was generally unsuccessful. Oxybutynin HCl in sufficient dosages seems to be effective in the treatment of enuretic patients with IBSF.